Use of BCG as an immunostimulant in the surgical treatment of carcinoma of lung: a five-year follow-up report

Abstract

Sixty consecutive surviving patients treated with subdermal BCG (5 X 10(6) organisms) have been followed up for five years after resection of lung carcinoma. A control group of the previous 60 consecutive surviving patients not treated with BCG was similarly studied. We found no statistical evidence that the administration of BCG by the method described influenced the five-year survival rate, nor has any effective action upon involved lymph nodes or small metastases been demonstrated.